Serina Therapeutics Completes Sentinel Dosing In Group 1 Of Its Phase 1b Study Of SER-252 To Treat Parkinson's Disease

Benzinga Newsdesk www.benzinga.com Neutral 91.2%

Neg 0% Neu 91.2% Pos 0%

https://s204.q4cdn.com/984998601/files/doc_news/2026/Jul/09/Serina_SER252_PR_June_29_2026-July-8th-2026.pdf

Comments

No comments yet. Be the first!